Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2023-11-07 Earnings Release
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Försäljningsdata för Leqembi® för Q3 2023 publicerade – sålde för 0,4 miljarder yen under perioden
Earnings Release Classification · 1% confidence The document is a press release from BioArctic AB announcing sales data for their product Leqembi for Q3 2023. It provides specific financial highlights (sales figures and royalty amounts) and explicitly mentions that the full interim report will be published the following day. Since this is an initial announcement of financial highlights rather than the full report itself, it falls under the Earnings Release category. Q3 2023
2023-11-07 Swedish
LEQEMBI® Q3 2023 sales published – 0.4 billion yen recorded in the period
Regulatory Filings Classification · 1% confidence The document is a press release issued by BioArctic AB regarding the sales figures of their partner's product (LEQEMBI) for the third quarter. It provides specific financial data (0.4 billion yen sales, 2.5 million SEK royalty) and explicitly mentions that the company's complete interim report will be published the following day. Since this is a short announcement of financial highlights rather than the full interim report itself, and it does not fit into specific categories like M&A or Board changes, it is classified as a Regulatory Filing (RNS) under the fallback category for general corporate announcements.
2023-11-07 English
BioArctic presents Nomination Committee
Governance Information Classification · 1% confidence The document is a press release announcing the composition of the Nomination Committee following the previous Annual General Meeting (AGM) and outlining its responsibilities for the upcoming 2024 AGM. It details the appointment of members representing major shareholders and specifies the topics the committee will prepare proposals for (e.g., Board fees, auditor election). This content directly relates to the governance structure and preparation for shareholder meetings, specifically concerning board and committee appointments, which falls under Board/Management Information (MANG) or Governance Information (CGR). However, the core subject is the composition and function of the committee responsible for nominating directors and setting AGM agendas, which is a key aspect of corporate governance. Given the specific focus on the Nomination Committee's structure and mandate, Governance Information (CGR) is a strong fit, as it covers internal rules and board structure. It is not a general AGM presentation (AGM-R) or a proxy statement (PSI), but rather an announcement about the governance body responsible for nominations.
2023-10-20 English
BioArctic presenterar valberedningen
AGM Information Classification · 1% confidence The document is a press release titled "BioArctic presenterar valberedningen" (BioArctic presents the Nomination Committee). It details the composition of the Nomination Committee based on shareholder structure as of September 30, 2023, names the appointed members, and outlines the committee's tasks for the upcoming 2024 Annual General Meeting (AGM). This content directly relates to the preparatory steps and governance structure surrounding the AGM, specifically concerning the nomination of directors and setting remuneration. This falls under the scope of AGM-related materials, but since it is an announcement about the committee formation rather than the meeting presentation itself, it is most closely aligned with general governance or AGM preparation. Given the specific options, the content is about the structure and process leading up to the AGM, which is often covered in proxy materials (DEF 14A or PSI), but the core subject is the 'Valberedning' (Nomination Committee). Since the document announces the composition of the committee whose purpose is to propose board members and remuneration for the AGM, and it is a formal announcement, it relates strongly to AGM procedures. However, none of the codes perfectly capture 'Nomination Committee Announcement'. AGM-R is for presentations *at* the AGM. PSI is for Proxy Solicitation. Given the focus on board composition and shareholder rights related to nominations, and the fact that this is a formal announcement regarding AGM preparation, AGM-R is the closest fit among the provided options that deal with shareholder meetings and board structure, although it is technically a pre-AGM governance announcement. If 'Governance Information' (CGR) were broader, it might fit there, but AGM-R specifically covers meeting-related structures.
2023-10-20 Swedish
Number of shares and votes in BioArctic AB (publ) as of September 29, 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release announcing a change in the total number of shares and votes following the issuance of new shares due to the exercise of stock options. This directly relates to a change in the company's capital structure (share count). Reviewing the definitions, 'Share Issue/Capital Change' (SHA) is the most appropriate category for announcements detailing the issuance of new shares and the resulting total share count. It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it pertains to a specific capital event.
2023-09-29 English
Antal aktier och röster i BioArctic AB (publ) per den 29september 2023
Share Issue/Capital Change Classification · 1% confidence The document is a press release ("Pressmeddelande") dated September 29, 2023, announcing the total number of shares and votes in BioArctic AB as of that date. It specifically mentions the issuance of 73,000 B-shares due to the exercise of stock options from an employee stock option program. This action directly relates to a change in the company's capital structure (issuance of new shares). This fits the definition of 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a general earnings release (ER), an interim report (IR), or a director's dealing (DIRS).
2023-09-29 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.